Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: A meta-analysis of randomized trials

Journal of the American Society of Nephrology

Volumn 15, Issue 12, 2004, Pages 3192-3206

  Lim, Wendy ^a   Cook, Deborah J ^a   Crowther, Mark A ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBASE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; URINARY EXCRETION; VASCULAR ACCESS;

EID: 9644290897     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000145014.80714.35     Document Type: Article

References (50)

1. Could MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130: 800-809, 1999
2. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC: The clinical use and laboratory monitoring of low-molecular-weight-heparin, danaparoid, hirudin and related compounds, and argatroban: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med 122: 799-807, 1998
3. Gerlach AT, Pickworth KK, Seth SK: Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency. Pharmacotherapy 20: 771-775, 2000
4. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119: 64S-94S, 2001
5. Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antmann EM: Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143: 753-759, 2002
6. Spinler SA, Inverse SM, Cohen M, Goodman SG, Stringer KA, Antimann EM: Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146: 33-41, 2003
7. Nagge J, Crowther M, Hirsh J: Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 162: 2605-2609, 2002
8. Ljunberg B, Jacobson SH, Lins LE, Pejler G: Effective anticoagulation by a low molecular weight heparin (fragmin) in haemodialysis with a highly permeable polysulphone membrane. Clin Nephrol 38: 97-100, 1992
9. Singer M, McNally T, Screaton G, Mackie I, Machin S, Cohen SL: Heparin clearance during continuous veno-venous haemofiltration. Intensive Care Med 20: 212-215, 1994
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17: 1-12, 1996
11. Anastassiades E, Ireland H, Flynn A, Lane DA, Curtis JR: A low-molecular-weight heparin (kabi 2165, "fragmin") in repeated use for haemodialysis: Prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin. Nephrol Dial Transplant 5: 135-140, 1990
12. Lai KN, Wang AYM, Ho K, Szeto CC, Li M, Wong LKS, Yu AWY: Use of low-dose low molecular weight heparin in hemodialysis. Am J Kidney Dis 28: 721-726, 1996
13. Koutsikos D, Fourtounas C, Kapetanaki A, Dalamanga A, Tzanatos H, Agroyannis B, Kopelias I, Bosiolis B, Rammos G, Bovoleti O, Sallum G, Darema M: A cross-over study of a new low molecular weight heparin (Logiparin) in hemodialysis. Int J Artif Organs 19: 467-471, 1996
14. Kerr PG, Mattingly S, Lo A, Atkins RC: The adequacy of fragmin as a single bolus dose with reused dialyzers. Artif Organs 18: 416-419, 1994
15. Hafner G, Klingel R, Wandel E, Ehrenthal W, Konheiser U, Lotz J, Kohler H, Prellwitz W: Laboratory control of minimal heparinization during haemodialysis in patients with a risk of haemorrhage. Blood Coagul Fibrinolysis 5: 221-226, 1994
16. Suzuki T, Ota K, Naganuma S, Koshikawa S, Hirasawa Y, Nakagawa S, Otsubo O, Akizawa T: Clinical application of Fragmin (FR-860) in hemodialysis: Multicenter cooperative study in Japan. Semin Thromb Hemost 16[Suppl]: 46-54, 1990
17. Shinoda T, Arakura H, Katakura M, Shirota T, Nakagawa S: Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis. Artif Organs 14: 413-415, 1990
18. Bambauer R, Rucker S, Weber U, Kohler M: Comparison of low molecular weight heparin and standard heparin in hemodialysis. ASAIO Trans 36: M646-M649, 1990
19. Dieval J, Moriniere P, Gross S, d'Azemar P, Fournier A, Delobel J: Influence of thromboembolism prophylaxis by low molecular weight heparin CY 216 (Fraxiparine) on several parameters of haemostasis in patients under dialysis and receiving either unfractionated heparin or CY 216. Thrombosis Res 58: 555-560, 1990
20. Moriniere P, Dieval J, Bayrou B, Roussel B, Renaud H, Fournier A, Delobel J: Low-molecular-weight heparin Fraxiparin in chronic hemodialysis. A dose-finding study. Blood Purif 7: 301-308, 1989
21. Schrader J, Kandt M, Zurcher C, Kostering H, Scheler F: Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients. Haemostasis 16[Suppl 2]: 48-58, 1986
22. Hofbauer R, Moser D, Frass M, Oberbauer R, Kaye AD, Wagner O, Kapiotis S, Druml W: Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 56: 1578-1583, 1999
23. Schrader J, Rieger J, Muschen H, Stibbe W, Kostering H, Kramer P, Scheler F: [Use of low molecular-weight heparin in hemodialysis patients]. [German]. Klin Wochenschr 63: 49-55, 1985
24. Vukusich A, Avalos C, Orellana G, Cifuentes C, Rivas J, Calderon F: [Anticoagulation in hemodialysis with a single dose of low molecular weight heparin]. [Spanish]. Rev Med Chil 123: 735-741, 1995
25. Przedlacki J, Bogdanska-Straszynska B, Sawicka B, Wlodarczyk D, Sladowska B, Ajewski M, Wasiak K, Gellert R: [Antithrombotic activity of low molecular weight heparin (enoxaparin) during hemodialysis in patients with terminal kidney failure]. [Polish]. Pol Arch Med Wew 91: 438-445, 1994
26. Al-Arrayed S, Seshadri R: Use of low molecular weight heparin for hemodialysis: A short term study. Saudi J Kidney Dis Transplant 13: 146-150, 2002
27. Kanamori N: Pathogenic effects of unfractionated heparin on hypercoagulability and vasculoendothelial dysfunction of regular hemodialysis patients. J Showa Med Assoc 53: 1993
28. Borm JJ, Krediet R, Sturk A, ten Cate JW: Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: A randomized cross-over study. Haemostasis 16[Suppl 2]: 59-68, 1986
29. Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Kostering H, Seidel D, Scheler F: Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 33: 890-896, 1988
30. Anastassiades E, Lane DA, Ireland H, Flynn A, Curtis JR: A low molecular weight heparin ("fragmin") for routine hemodialysis: A crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. Clin Nephrol 32: 290-296, 1989
31. Nurmohamed MT, ten Cate J, Stevens P, Hoek JA, Lins RL, ten Cate JW: Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin. ASAIO Trans 37: M459-M461, 1991
32. Ryan KE, Lane DA, Flynn A, Shepperd J, Ireland HA, Curtis JR: Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis. Thromb Haemost 66: 277-282, 1991
33. Harenberg J, Haaf B, Dempfle CE, Stehle G, Heene DL: Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay. Nephrol Dial Transplant 10: 217-222, 1995
34. Janssen MJ, Deegens JK, Kapinga TH, Beukhof JR, Huijgens PC, van Loenen AC, van der MJ: Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. Kidney Int 49: 806-813, 1996
35. Moia M, Graziani G, Tenconi PM, Martinelli I, Ponticelli C: Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients. Ann Ital Med Int 12: 67-71, 1997
36. Saltissi D, Morgan C, Westhuyzen J, Healy H: Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 14: 2698-2703, 1999
37. Apsner R, Buchmayer H, Lang T, Unver B, Speiser W, Sunder-Plassmann G, Horl WH: Simplified citrate anticoagulation for high-flux hemodialysis. Am J Kidney Dis 38: 979-987, 2001
38. Reach I, Luong N, Chastang C, Chakroun M, Mirshahi S, Mirshahi MC, Soria J, Desmichels D, Baumelou A: Dose effect relationship of reviparin in chronic hemodialysis: A crossover study versus nadroparin. Artif Organs 25: 591-595, 2001
39. Stefoni S, Cianciolo G, Donati G, Coli L, La Manna G, Raimondi C, Dalmastri V, Orlandi V, D'Addio F: Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. Nephron 92: 589-600, 2002
40. Lord H, Jean N, Dumont M, Kassis J, Leblanc M: Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol 22: 58-66, 2002
41. Polkinghorne KR, McMahon LP, Becker GJ: Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 40: 990-995, 2002
42. Liu ZQ, Wang L: Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis. Di Yi Junyi Daxue Xuebao 22: 942-943, 2002
43. Beijering RJR, ten Cate H, Stevens P, Vanholder R, Van Dorp WT, Van Olden RW, Wickstrom B, Sprogel P, ten Cate JW: Randomised long-term comparison of tinzaparin and dalteparin in haemodialysis. Clin Drug Invest 23: 85-97, 2003
44. Ireland H, Lane DA, Curtis JR: Objective assessment of heparin requirements for hemodialysis in humans. J Lab Clin Med 103: 643-652, 1984
45. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M: The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins and heparin. Blood 59: 1239-1245, 1982
46. Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, Manthous CA: Anticoagulation in hospitalized patients with renal insufficiency. A comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 125: 856-863, 2004
47. Crowther MA, Berry LR, Monagle PT, Chan AKC: Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116: 178-186, 2002
48. Hainer JW, Sherrard DJ, Swan SK, Barrett SJ, Assaid CA, Fossler MJ, Cox DS, Williams RM, Pittenger AL, Stephenson CA, Hua TA: Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal patients undergoing chronic hemodialysis. Am J Kidney Dis 40: 531-538, 2002
49. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G: A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thrombo-embolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 160: 181-188, 2000
50. Quinlan DJ, McQuillan A, Eikenboom JW: Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. Ann Intern Med 140: 175-183, 2004